Krakow-based Selvita S.A. has announced it will spin out its oncology unit this year resulting in two public companies, a CRO and a cancer therapeutics developer.
The CHF22.5m Series A financing round of the Swiss specialist for autoimmune diseases was led by Sofinnova Partners and New Enterprise Associates together with contributions of existing investors.
French liver disorder specialist Genfit SA has announced the pricing of its Nasdaq IPO of ADS and European private placement.
Evotec AG and The Mark Foundation for Cancer Research have inked a R&D collaboration aimed at developing novel immunooncological drugs
US-Austrian arenavirus-based cancer and infectious diseases specialist Hookipa has has filed a prospectus for an US$86M Nasdaq IPO.
A research team from Germany and Mexico has successfully targeted uveal melanoma (UM), the most common type of eye cancer.
Pfizer Inc has paid €45m upfront to French gene therapy specalist Vivet Therapeutics in a licence option deal for Vivet’s preclinical Wilson disease candidate VTX-801.
After positive preliminary results of Sotio’s SOV02 trial in ovarian cancer had been presented last year, the final analysis confirmed the survival benefits. The Czech biotech company now plans to initiate a global Phase III study with its autologous cell-based immunotherapy also in this indication.
More than 330 experts joined the 2-day AMR Conference 2019 in Berlin. They called for rapid capital investments and economic incentives in the fight against antimicrobial resistance (AMR).
